Comparative Pharmacology
Head-to-head clinical analysis: ELELYSO versus LUMIZYME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELELYSO versus LUMIZYME.
ELELYSO vs LUMIZYME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human glucocerebrosidase; hydrolyzes glucocerebroside to glucose and ceramide, reducing accumulated glucocerebroside in lysosomes of macrophages.
Alglucosidase alfa is a recombinant form of human acid alpha-glucosidase (GAA), which hydrolyzes lysosomal glycogen. It provides exogenous enzyme to reduce accumulation of glycogen in lysosomes.
60 U/kg administered intravenously over 60 minutes every 2 weeks.
5 mg/kg administered intravenously once every 2 weeks.
None Documented
None Documented
Mean terminal elimination half-life ranges from 6.1 to 8.9 minutes after intravenous infusion; rapid clearance due to receptor-mediated uptake.
Terminal half-life: 1.1–3.5 hours (mean 2.2 hours) after IV infusion; due to rapid uptake into lysosomes, shorter than many enzymes.
Primarily catabolized via peptide hydrolysis; renal excretion of small peptide fragments and amino acids; less than 1% excreted unchanged in urine.
Eliminated via reticuloendothelial system; no significant renal or biliary excretion. <5% recovered unchanged in urine.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy